Effectiveness of delivery routesinjectable versus oral/nasal absorption, stability of formulation
Pablo de la Cueva has participated as consultant and/or investigator and/or speaker for the following pharmaceutical companies: Abbvie, Almirall, BMS, Boehringer-Ingelheim, Celgene, Janssen Cilag, LEO Pharma, Lilly, MSD, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, and UCB
Mitigation strategies include frequent glucose monitoring when changes are made to insulin dosage, oral hypoglycemic medications, meal patterns, physical activity, and in cases of renal or hepatic impairment or hypoglycemia unawareness, with consideration for dose reduction
Weinhold LC, Ahmad S, Pardini RS
After a review of the totality of information, including all clinical data generated to date for danuglipron and recent input from regulators, Pfizer has decided to discontinue development of the molecule
Devarshi PP, McNabney SM, Henagan TM